[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Penumbra Inc (PEN)

Penumbra Inc (PEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,475,794
  • Shares Outstanding, K 39,331
  • Annual Sales, $ 1,404 M
  • Annual Income, $ 177,690 K
  • EBIT $ 187 M
  • EBITDA $ 205 M
  • 60-Month Beta 0.71
  • Price/Sales 8.86
  • Price/Cash Flow 73.54
  • Price/Book 8.44

Options Overview Details

View History
  • Implied Volatility 27.86% (+1.53%)
  • Historical Volatility 9.17%
  • IV Percentile 42%
  • IV Rank 37.72%
  • IV High 56.95% on 10/20/25
  • IV Low 10.24% on 05/21/26
  • Expected Move (DTE 27) 17.85 (5.63%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 151
  • Volume Avg (30-Day) 218
  • Put/Call OI Ratio 2.26
  • Today's Open Interest 12,525
  • Open Int (30-Day) 11,673
  • Expected Range 299.35 to 335.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.18
  • Number of Estimates 2
  • High Estimate $1.20
  • Low Estimate $1.15
  • Prior Year $0.86
  • Growth Rate Est. (year over year) +37.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
315.81 +0.44%
on 06/18/26
329.67 -3.78%
on 05/22/26
-9.34 (-2.86%)
since 05/18/26
3-Month
315.81 +0.44%
on 06/18/26
338.98 -6.43%
on 03/19/26
-21.04 (-6.22%)
since 03/18/26
52-Week
221.26 +43.36%
on 11/03/25
362.41 -12.47%
on 01/21/26
+60.19 (+23.42%)
since 06/18/25

Most Recent Stories

More News
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT

The THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVT TM ) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid,...

PEN : 317.20 (+0.33%)
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke

THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal

PEN : 317.20 (+0.33%)
Penumbra: Q1 Earnings Snapshot

Penumbra: Q1 Earnings Snapshot

PEN : 317.20 (+0.33%)
Penumbra, Inc. Reports First Quarter 2026 Financial Results

ALAMEDA, Calif. , May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.

BSX : 45.29 (+0.76%)
PEN : 317.20 (+0.33%)
Penumbra's First Quarter Without Guidance May Redefine How the Market Values the Acquisition

Barchart Research What to Expect from PEN Earnings PEN Generated May 5, 2026 Current Price $323.86 EPS Estimate $$1.11 Consensus Rating Hold Average Move 8.04% Penumbra's First Quarter Without Guidance...

PEN : 317.20 (+0.33%)
Penumbra's Thrombectomy Momentum: The Quarter Boston Scientific Bet Fourteen Billion Dollars On

Barchart Research What to Expect from PEN Earnings PEN Generated April 28, 2026 Current Price $325.99 EPS Estimate $$1.11 Consensus Rating Hold Average Move 8.04% Penumbra's Thrombectomy Momentum: The...

PEN : 317.20 (+0.33%)
1 Mid-Cap Stock on Our Buy List and 2 We Ignore

1 Mid-Cap Stock on Our Buy List and 2 We Ignore

RBA : 110.57 (+3.03%)
PEN : 317.20 (+0.33%)
FTV : 61.03 (+0.58%)
Are OMEX, PEN, SNCY, CWAN Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

OMEX : 0.8976 (-1.65%)
SNCY : 16.17 (-1.52%)
PEN : 317.20 (+0.33%)
CWAN : 24.29 (+0.12%)
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Penumbra , Inc....

BSX : 45.29 (+0.76%)
PEN : 317.20 (+0.33%)
Penumbra (NYSE:PEN): Strongest Q4 Results from the Medical Devices & Supplies - Cardiology, Neurology, Vascular Group

Penumbra (NYSE:PEN): Strongest Q4 Results from the Medical Devices & Supplies - Cardiology, Neurology, Vascular Group

PEN : 317.20 (+0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access...

See More

Key Turning Points

3rd Resistance Point 319.12
2nd Resistance Point 318.18
1st Resistance Point 317.69
Last Price 317.20
1st Support Level 316.26
2nd Support Level 315.32
3rd Support Level 314.83

See More

52-Week High 362.41
Last Price 317.20
Fibonacci 61.8% 308.49
Fibonacci 50% 291.83
Fibonacci 38.2% 275.18
52-Week Low 221.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.